Direkt zum Seiteninhalt, zur Hauptnavigation, zur Unternavigation, zur Fußzeile.

immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer.

Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies.

We aim to achieve this by using multiple and relevant peptides that specifically activate T cells, specialized white blood cells, of the patient’s immune system against cancer cells. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors.

Our lead product, IMA901 for the treatment of kidney cancer, is in a global phase 3 clinical trial. Our other clinical-stage products are IMA910 for the treatment of colorectal cancer, which has completed a multi-center phase 2 clinical trial, and IMA950 for the treatment of brain cancer, which is in phase 1 clinical studies with partners. We also have active early-stage programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer being developed in collaboration with our partner Roche. 


Latest News

-- 19 September 2014
immatics to present at ESMO 2014 (September 26-30, 2014) in Madrid, Spain
Sunday, September 28 1pm – 2pm Final results from a Cancer Research UK first in man Phase I trial of ... read more
-- 16 July 2014
immatics receives €22 million final tranche of Series D fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics ’ Human ... read more
-- 13 July 2014
immatics congratulates the German team on winning the 2014 Football World Cup! ... read more


Renal cell cancer phase 3 clinical trial

Drug: Peptide-based renal cell cancer vaccine IMA901...read more

Participating countries: France, Germany, Hungary, Italy, Poland, Russia, UK, USA, Netherlands, Norway


Glioblastoma phase 1 clinical trials
Drug: Peptide-based glioma vaccine IMA950...read more
Participating countries: UK & USA